title: [Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?].
abstract: OBJECTIVE
  To review the guideline recommendations on aspirin use in primary prevention of cardiovascular diseases.
  
  
  METHODS
  Systematic review. The search was made by condition, treatment and type of prevention.
  
  
  METHODS
  Science Citation Index, SCOPUS, PubMed, Spanish Ministry of Health, World Health Organisation, web sites of national and international scientific societies.
  
  
  METHODS
  Two investigators independently reviewed all the guidelines. Specific topics assessed: a) use of antiplatelet treatment in primary prevention b) identification of target population c) identification of recommended dosage, d) identification of criteria of aspirin use, e) publications in English and/or Spanish, f) dissemination at national (Spain) or international level.
  
  
  RESULTS
  Nine guidelines on primary prevention and 5 guidelines on diabetes were reviewed. Most of them recommended low dose aspirin ranging between 75mg and 325mg per day. All the guidelines recommend a specifc level of coronary risk to define the target population to be treated, showing high variability in risk tables used and in the level of risk which should be used to recommend treatment. The diabetes guidelines do not define any level of risk. Three guidelines recommend the use of aspirin when blood pressure is well controlled.
  
  
  CONCLUSIONS
  There is high variability among guidelines in terms of the level of risk from which patients should be treated, and also in dosages. Most of the guidelines recommend the use aspirin in diabetics, although some discrepancies exist among international panels, and even in different documents of the same scientific society.
authors.affiliation: Unidad de Investigación, Equipo de Atención Primaria Sardenya, Barcelona, España. cbrotons@eapsardenya.cat
authors.forename: Carlos
authors.initials: C
authors.lastname: Brotons Cuixart
authors.forename: Irene
authors.initials: I
authors.lastname: Moral Peláez
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D006801:Humans; D017410:Practice Guidelines as Topic; D011322:Primary Prevention
chemical_list: D001241:Aspirin
references.citation: Heart. 2007 Feb;93(2):172-6
references.pmid: 17090561
references.citation: Circulation. 1991 Jan;83(1):356-62
references.pmid: 1984895
references.citation: BMJ. 2009 Nov 06;339:b4531
references.pmid: 19897665
references.citation: BMJ. 2008 Oct 16;337:a1840
references.pmid: 18927173
references.citation: Heart. 2005 Dec;91 Suppl 5:v1-52
references.pmid: 16365341
references.citation: Circulation. 1998 May 12;97(18):1837-47
references.pmid: 9603539
references.citation: Circulation. 2002 Dec 17;106(25):3143-421
references.pmid: 12485966
references.citation: Aten Primaria. 2001 Jun 15;28(1):74-9
references.pmid: 11412582
references.citation: Eur Heart J. 2007 Jan;28(1):88-136
references.pmid: 17220161
references.citation: Circulation. 2007 Mar 20;115(11):1481-501
references.pmid: 17309915
references.citation: Stroke. 1991 Mar;22(3):312-8
references.pmid: 2003301
references.citation: Circulation. 2002 Jul 16;106(3):388-91
references.pmid: 12119259
references.citation: JAMA. 2008 Nov 12;300(18):2134-41
references.pmid: 18997198
references.citation: J Hypertens. 2009 Nov;27(11):2121-58
references.pmid: 19838131
references.citation: Chest. 2008 Jun;133(6 Suppl):199S-233S
references.pmid: 18574266
references.citation: Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 Suppl 2:S1-113
references.pmid: 17726407
references.citation: Eur Heart J. 2003 Jun;24(11):987-1003
references.pmid: 12788299
references.citation: Circulation. 2007 Jan 2;115(1):114-26
references.pmid: 17192512
references.citation: Lancet. 2009 May 30;373(9678):1849-60
references.pmid: 19482214
references.citation: Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
references.pmid: 20042772
references.citation: Ann Intern Med. 2009 Mar 17;150(6):396-404
references.pmid: 19293072